Skip to main content
TipRanks
Go Ultimate75% OFF

Douglas Swirsky Insider Profile

4 Followers

Douglas Swirsky, Director at Cellectar Biosciences, holds 25.00K shares in Cellectar Biosciences (Ticker: CLRB), holds 50.00K shares in Opus Genetics (Ticker: IRD), holds 242.50K shares in GenVec Inc (Ticker: GNVC). Most recently, Douglas Swirsky Bought ― shares of Cellectar Biosciences on Sep 14, 2021 for an estimated value of $26.00K.

Douglas Swirsky's Trading History

CLRB
Cellectar Biosciences
Sep 14, 2021DirectorInformative Buy26.00K$25.25K
IRD
Opus Genetics
Jan 30, 2019President & CEO, DirectorInformative Buy31.50K$202.00K
GNVC
GenVec Inc
Sep 16, 2016―Informative Buy5.00K$1.74M
FCSC
Fibrocell Science
―――$0.00
MTVA
MetaVia
―Director――
PTXTQ
Pernix Therapeutics
――――

You May Also Like

Douglas Swirsky insider profile FAQ

What is the percentage of profitable transactions made by Douglas Swirsky?
The percentage of profitable transactions made by Douglas Swirsky is 0%.
What is the average return per transaction made by Douglas Swirsky?
The average return per transaction made by Douglas Swirsky is -70.80%.
What stocks does Douglas Swirsky hold?
Douglas Swirsky holds: CLRB, GNVC, IRD, PTXTQ, MTVA, FCSC stocks.
What was Douglas Swirsky’s latest transaction?
Douglas Swirsky’s latest transaction was an Informative Buy of $26.00K.
What was Douglas Swirsky's most profitable transaction?
Douglas Swirsky’s most profitable transaction was an Informative Buy of CLRB stock on September 14, 2021. The return on the trade was -56.00%.
What is Douglas Swirsky's role in Cellectar Biosciences?
Douglas Swirsky's role in Cellectar Biosciences is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.